S&P 500
(0.03%) 5 088.80 points
Dow J
(0.16%) 39 132 points
Nasdaq
(-0.28%) 15 997 points
Oil
(-0.43%) $76.16
Gas
(10.17%) $1.766
Gold
(-0.44%) $2 040.40
Silver
(0.35%) $23.06
Platinum
(-0.75%) $902.80
USD/EUR
(0.06%) $0.925
USD/NOK
(0.17%) $10.55
USD/GBP
(0.07%) $0.790
USD/RUB
(0.11%) $93.70

Realtime updates for Jiangsu Recbio Technology [2179.HK]

Exchange: HKSE Sector: Healthcare Industry: Biotechnology
Last Updated21 Feb 2024 @ 00:43

-4.72% HKD 8.08

Live Chart Being Loaded With Signals

Commentary (21 Feb 2024 @ 00:43):

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China...

Stats
Today's Volume 205.00
Average Volume 19 036.00
Market Cap 2.53B
Last Dividend HKD0 ( N/A )
Next Dividend HKD0 ( N/A )
P/E -5.50
ATR14 HKD0 (0.00%)

Jiangsu Recbio Technology Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jiangsu Recbio Technology Financials

Annual 2022
Revenue: HKD0
Gross Profit: HKD0 (0.00 %)
EPS: HKD-1.520
Q4 2021
Revenue: HKD0.00
Gross Profit: HKD0.00 (0.00 %)
EPS: HKD-0.284
Q4 2020
Revenue: HKD0.00
Gross Profit: HKD0.00 (0.00 %)
EPS: HKD-0.221

Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.

AboutLive Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators